The Effects of Serratus Plane Block Performed Under Direct Vision on Post-operative Pain in Breast Surgery

NCT ID: NCT02555423

Last Updated: 2015-09-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to determine the effectiveness of serratus place block in the control of post-operative pain following mastectomy. The investigators will compare one group of patients receiving serratus plane block and wound infiltration to a control group receiving a saline injection into serratus anterior and wound infiltration with local anaesthetic only. The investigators will compare our results to the National Mastectomy and Breast Reconstruction Audit's reported rate of 6.2% of patients reporting severe pain following mastectomy to see if there is an improvement of the national standard. In the serratus block group, the investigators expect a 50% decrease in the number of patients who report severe pain day one post operatively.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients who undergo mastectomy +/- sentinel node biopsy +/- axillary clearance +/- implant reconstruction will be eligible for the study. Patients will be consented by Mr Davies preoperatively in the breast clinic at Kingston Hospital to be randomly allocated to one of two groups.

The study will be double blinded and patients will be randomly allocated in to one of two groups as detailed below:

Group 1 - Control Group The first group will act as the control group and will receive wound infiltration with the full amount of local anaesthetic (40mls) around the drain sites and axillary wound, if present, as is standard practice. They will also receive a 20ml injection of 0.9% saline deep to serratus anterior under direct observation. Infiltration of saline will be delivered into 2-3 muscular slips (typically ribs 4-6) in the anterior axillary line. The local anaesthetic will be prepared according to body weight and a dose of 0.375% of chirocaine will be used with the addition of 1:200000 adrenaline and 1 microgram/kg of clonidine.

Group 2 - Serratus Plane Block Group

The second group will receive a serratus plane block and wound infiltration as described below:

The serratus plane block will be conducted by injecting 50% of the total available chirocaine 0.375% with adrenaline and clonidine (20mls) deep to serratus anterior under direct observation. Infiltration will be delivered into 2-3 muscular slips (typically ribs 4-6) in the anterior axillary line. The remaining 50% of local anaesthetic (20mls) will be administered by wound infiltration around the drain sites and axillary wound if present along with a 20ml 0.9% saline injection.

For clarity, please see the table summary below detailing the volumes and locations of local anaesthetic and saline injections in both groups:

20ml local anaesthetic delivered as a serratus block 20ml Saline delivered deep to serratus anterior 20ml local anaesthetic and 20ml saline wound and drain site infiltration 40ml local anaesthetic wound and drain site infiltration Control Group X √ X √ Serratus Group √ X √ X

The purpose of the saline injections is to blind the trial to the surgeon delivering the serratus block.

The anaesthesia for all patients in both groups will be induced using a combination of 0.25mg/kg ketamine, propofol and fentanyl according to standard anaesthetic protocol. All patients will receive 10mg IM morphine intraoperatively. All patients will have regular simple analgesia such as paracetamol and ibuprofen and PRN opiates (tramadol 50-100mg PRN 8 hourly) prescribed for post-operative adjunct pain management.

Patients will be blinded to which group they are randomly allocated to. Written consent and information sheets will be provided to patients and a letter sent to their GP confirming participation in the study.

Data on pain scores and the use of analgesia in recovery, the use of analgesia overnight, the presence of nausea and the pain score and mobilisation status one day after the operation will be collected. The pain score will be assessed using a standard numerical rating scale from 0-10 to score their pain subjectively where:

* 0 = No Pain
* 1-3 = Mild Pain (interferes a little with activities of daily living)
* 4-6 = Moderate Pain (interferes significantly with activities of daily living)
* 7-10 = Severe Pain (unable to perform activities of daily living)

Patients will also be followed up and one week and 3 months after their surgery to determine their recovery and the presence of any pain. This data will be collected using the FACT - B: Quality of Life Assessment 1 questionnaire.

All collected data will only be stored on NHS trust computer systems.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post-operative Pain Serratus Block Breast Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

SUPPORTIVE_CARE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Local anaesthetic - chirocaine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who undergo mastectomy +/- sentinel node biopsy +/- axillary clearance +/- implant reconstruction will be eligible for the study

Exclusion Criteria

* Patients under the age of 18.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kingston Hospital NHS Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Marcus Hards

Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

179669

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Erector Spinae Block vs. Placebo Block Study
NCT03978780 NOT_YET_RECRUITING NA
Pectoral Nerve Blockade in Mastectomy
NCT01943240 WITHDRAWN PHASE4